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Delirium Associated with Olanzapine Therapy  
in an Elderly Male with Bipolar Affective Disorder
Atypical antipsychotic medications are commonly used to treat symptoms of delirium. Olan-
zapine has been successfully used in the treatment of delirium. However, there have been few 
case reports of delirium associated with olanzapine. We hereby report a case of delirium asso-
ciated with olanzapine therapy. Possible risk factors and underlying pathogenesis is dis-
cussed.   Psychiatry Investig 2010;7:153-154
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Introduction
Olanzapine is a second generation antipsychotic agent approved for management of schizo-
phrenia as well as mania. The package insert for olanzapine includes a warning regarding pos-
sibility of adverse cerebrovascular events with its use in elderly patients with dementia.
1 It has 
also been reported that elderly patients have dose requirements similar to the young adults.
2 
Antipsychotic olanzapine has been reported to be useful in the management of symptoms 
of delirium.
3,4 However, contrary to this, there are few reports of olanzapine related delirium.
5-7 
We hereby report a case of olanzapine associated delirium developing in an elderly male with 
bipolar affective disorder (BPAD), because of its rarity. 
Case
82 years old married male working as a farmer was suffering from bipolar affective disor-
der for the last 50 years. He had multiple episodes of mania and depression which were treat-
ed with various psychotropic medications. He was maintaining well for the last 3 years and 
hence had stopped all medications and was only taking lorazepam 1 mg on as and when re-
quired basis for sleep.
He now presented with complaints of over talkativeness, big talks, over activity, decreased 
need for sleep and excessive cheerfulness for the last 1 month. There was no associated his-
tory of fits, urinary incontinence, fever, forgetfulness or other symptoms suggestive of organic-
ity. His personal and family history were non significant. Medical history revealed patient to 
be suffering from benign hypertrophy of prostrate grade I. Mental status examination revealed 
elated affect, increased psychomotor activity, grandiose ideation and absent insight. His Mini 
Mental Status Examination score was 25/30. A diagnosis of BPAD currently manic episode 
was made. He was started on divalproex 250 mg HS, olanzapine 5 mg Hs increased to 10 mg 
HS after 5 days and lorazepam 2 mg HS. The patient after taking medications for about two 
days reported excessive sleep and consequently stopped divalproex. He however, continued 
olanzapine and lorazepam in the dose prescribed. However, after about two days of 10 mg 
olanzapine, the family members noticed that the patient would get up in the night at around 
2.00 a.m. He would then start roaming about in the house, would not recognize the family 
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members, would start saying that he should go to work and 
would not recognize the time and place also. He would urinate 
at wrong places. On occasions, he would start picking up the 
bed sheets or the pillow covers saying that ants were sitting 
there, though the family members would not see anything 
there. He would on occasions stand on the table and start sp-
eaking to self or would try to reach for some invisible objects 
in the air. He would then go to sleep at around 5:00 a.m. in the 
morning and would get up at 9:00 a.m. He would not recol-
lect the happenings of the night time. His day time activities 
however, started to decrease. These episodes continued regu-
larly every night. A diagnosis of delirium was made and he 
was investigated. Hematological investigations, including se-
rum electrolytes, liver function tests were normal except for 
increased blood Urea-54 mg% (15-45 mg% normal range) and 
increased S. Creatinine-2 mg% (0.5-1.0 mg% normal range). 
Computed tomography scan head was normal. Lorazepam 
was increased to 4 mg per day and olanzapine was continued 
in the same dose. The manic symptoms decreased in intensity. 
The family members then stopped olanzapine on their own. 
Two days after this, the family members reported improve-
ment in delirious symptoms. He would now take only loraz-
epam 4 mg per day and would have improvement in manic as 
well as the abnormal behavior suggestive of delirium. Hemato-
logical investigations done after the improvement in abnormal 
behavioral episodes of delirium revealed similar findings. 
Discussion
Our case was diagnosed as a case of delirium as per ICD-10 
criteria.
8 The history given revealed features like fluctuating 
consciousness, impaired recent memory, disorientation, per-
ceptual disturbances in the from of visual hallucinations, dis-
turbed sleep wake cycle, picking up movements, and sun down-
ing phenomenon. An increase in dose upto 10 mg per day of ol-
anzapine precipitated agitated delirium in our patient. The Na-
ranjo probability scale
9 indicates that olanzapine was the pro-
bable cause of delirium. Though our patient had increased blood 
urea and serum creatinine, but this persisted even after resolu-
tion of delirium. Delirium in our case responded to stopping 
of olanzapine. Patient was not on other medications other than 
lorazepam which was being continued much before the onset of 
delirium and was continuing even after resolution of delirium. 
There was no other associated medical condition at the time 
of delirium. However, one of the limitations with our report is 
the outpatient follow up of the patient.
Traditionally, delirium has been treated with typical antipsy-
chotics, particularly haloperidol. However, with the increas-
ing use of atypical antipsychotics, there have been several stud-
ies describing the successful use of these agents especially ol-
anzapine, for the treatment of delirium.
3,4,10,11 
Conversely, there have been few reports of delirium asso-
ciated with olanzapine. Most of these have been in patients with 
other risk factors for delirium like combination with lithium, 
intoxication with olanzapine, in patient with metastatic lung 
cancer with intractable nausea and in a case with mental re-
tardation, seizure disorder, and acute cellulites.
5,6,12,13 
Like our case, there has been report of a 76-year-old man, 
also a bipolar disorder patient who developed olanzapine re-
lated delirium.
7 However, patient was on higher dose (20-30 
mg) of olanzapine per day along with other psychotropic medi-
cations and had also developed systemic infection. 
The anticholinergic property of olanzapine might have con-
tributed to the pathophysiology of delirium induced by olanzap-
ine.
14 Old age and impaired renal function tests could have 
predisposed to the development of delirium.
To conclude, one must be cautious while using olanzapine 
even in low doses, in elderly patients. Further research is war-
ranted to identify the risk factors associated with olanzapine 
associated delirium. 
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